$ACH

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth ​ Gardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement ​ Company Announces Scott Lloyd as Chief Commercial Offic

Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.

Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.

Accendra Health (NYSE:ACH) said it will drop an at-the-market equity issuance plan, citing recent market conditions, and said the change will not affect operating results or prior financial guidance. The company expects two non-core asset sales to generate about $45 million in cash and reported no drawings on its $300 million revolver. It plans to name a CEO successor by mid-September 2026.

Accendra Health (NYSE: ACH) said CEO Edward A. Pesicka plans to retire by end-2026 and step down from the board before year-end. The board has started a successor search and will evaluate candidates to appoint a new president and CEO. The company cited prior transactions and management changes as part of the timing.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreemen

Accendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accendra Health Reports Second Quarter 2026 Financial Results Reduced Total Debt By $385 Million In Second Quarter CEO Ed Pesicka Announces Intention To Retire By The End of 2026 RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today r

ACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has in

Accendra Health Inc. (NYSE:ACH) said on June 23 it completed exchange offers for its 4.5% senior notes due 2029 and 6.625% senior notes due 2030. The notes were exchanged for new 9% senior secured first-lien notes due 2032 and 9.75% senior secured second-lien notes due 2033. Accendra expects to issue about $539.25 million first-lien notes and about $698.1 million second-lien notes, while S&P Global Ratings affirmed a 'B' issuer rating and moved outlook to stable.